11:38 AM EDT, 06/12/2024 (MT Newswires) -- Lantern Pharma ( LTRN ) said Wednesday it secured a composition of matter patent for its drug candidate LP-284 in Japan, the third country to grant this patent.

LP-284, which is being studied in a phase 1 clinical trial for treating relapsed or refractory non-Hodgkin's lymphoma and certain sarcomas, could potentially improve outcomes for 40,000 to 80,000 patients with blood cancers annually, the company said.

The drug candidate had previously received a similar patent from the US Patent and Trademark Office, with an expiry in early 2039. It also expects receiving similar patent rights for the drug candidate in Europe, China, Australia, Canada and Korea, the company said.

Price: 5.70, Change: +0.11, Percent Change: +1.97